References
Boasberg, P., Hamid, O., & O'Day, S. (2010). Ipilimumab: Unleashing the power of the immune system through CTLA-4 blockade. Seminars in Oncology, 37, 440-449. doi:10.1053/j.seminoncol.2010.09.004
Boyle, P., & Ferlay, J. (2005). Cancer incidence and mortality in Europe, 2004. Annals of Oncology, 16, 481-488. doi:10.1093/annonc/mdi098
Dummer, R., Hauschild, A., Guggenheim, M., Keilholz, U., & Pentheroudakis, G. (2012). Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Annals of Oncology, 23(Suppl. 7), vii86-vii91. doi:10.1093/annonc/mds229
Ferlay, J., Parkin, D. M., & Steliarova-Foucher, E. (2010). Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer, 46, 765-781. doi:10.1016/j.ejca.2009.12.014
Fong, L., & Small, E. J. (2008). Anticytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment. Journal of Clinical Oncology, 26, 5275-5283. doi:10.1200/JCO.2008.17.8954
Harmankaya, K., Erasim, C., Koelblinger, C., Ibrahim, R., Hoos, A., Pehamberger, H., & Binder, M. (2011). Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Medical Oncology, 28, 1140-1144. doi:10.1007/s12032-010-9606-0
Hoos, A., Ibrahim, R., Korman, A., Abdallah, K., Berman, D., Shahabi, V., … Humphrey, R. (2010). Development of ipilimumab: Contribution to a new paradigm for cancer immunotherapy. Seminars in Oncology, 37, 533-546. doi:10.1053/j.seminoncol.2010.09.015
Ibrahim, R. A., Berman, D. M., DePril, V., Humphrey, R. W., Chen, T., Messina, M., … Hoos, A. (2011). Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma [Abstract 8583]. Journal of Clinical Oncology, 29(Suppl.), 546s.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008). Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58, 71-96. doi:10.3322/CA.2007.0010
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007). Immunostimulatory monoclonal antibodies for cancer therapy. Nature Reviews. Cancer, 7, 95-106. doi:10.1038/nrc2051
O'Day, S. J., Hamid, O., & Urba, W. J. (2007). Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): A novel strategy for the treatment of melanoma and other malignancies. Cancer, 110, 2614-2627. doi:10.1002/cncr.23086
Pennock, G. K., Waterfield, W., & Wolchok, J. D. (2012). Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: How different are these from conventional treatment responses? American Journal of Clinical Oncology, 35, 606-611. doi:10.1097/COC.0b013e318209cda9
Robert, C., & Ghiringhelli, F. (2009). What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist, 14, 848-861.
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., … Wolchok, J. D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364, 2517-2526. doi:10.1056/NEJMoa1104621
Rubin, K. M. (2012). Managing immune-related adverse events to ipilimumab: A nurse's guide [Online exclusive]. Clinical Journal of Oncology Nursing, 16, E69-E75. doi:10.1188/12.CJON.E69-E75
Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10-29. doi:10.3322/caac.20138
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbe, C., … Hodi, F. S. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clinical Cancer Research, 15, 7412-7420. doi:10.1158/1078-0432.CCR-09-1624